Flexus Biosciences rakes in $38 mln Series B

By Iris Dorbian — 11 months ago

Flexus Biosciences has raised $38 million in Series B funding. The investors were Kleiner Perkins Caufield & Byers, The Column Group and Celgene. Also, the firm has named Dr. David Goeddel, a managing partner at TCG, to its board of directors and Dr. Alexander Rudensky as chairman of its clinical and scientific advisory board. Based in San Carlos, Calif., Flexus is a cancer immunotherapy firm.


Acceleron Pharma Inks $30M

4 years ago

Cambridge, Mass.-based Acceleron Pharma Inc. has raised $30 million in financing. The company said that strategic partner Celgene contributed to the round, along with “all other existing investors.” Acceleron has raised capital from Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. The new funds will be used to expand the company’s clinical stage pipeline.


Celgene Buying Gloucester Pharma For Up To $640 Million

By PEHub Administrator — 6 years ago

Celgene Corp. (Nasdaq: CELG) has agreed to acquire Gloucester Pharmaceuticals, a Cambridge, Mass.-based developer of oncology drugs. The deal is valued at up to $640 million, including a $340 million up-front cash payment and up to $300 million in earn-outs. Gloucester Pharma had raised over $130 million in VC funding, from firms like Apple Tree Partners, Novo AS, ProQuest Investments, Prospect Venture Partners and Rho Ventures.